Because inhibition of the PI3K/AKT/mTOR axis results in enhanced HER2 signalling in HER2-overexpressing breast cancer, especially in increased expression of HER2 and HER3 [23], targeting both pathways could prevent the development of resistance. The gene discussed is ERBB3; the disease is breast cancer.